ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1350	National Cancer Institute	Html	en	Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult central nervous system tumors.	treatment 0.515559 malignant tumor cells 0.227722 general information 0.262069 NCI-supported cancer 0.222651 cancer cells 0.27674 type 0.244277 spinal cord tumors 0.473603 clinical trial search 0.391071 brain tumors 0.2801 spinal cord 0.914442 tumor cells 0.493038 normal cells 0.296092	clinical trial 0.432056 clinical trials 0.701078 brain tumor 0.235359 brain 0.738045 PDQ summary 0.285532 tumors 0.535252 cancer clinical trials 0.361596 tumor 0.77091 radiation therapy 0.479169 grade 0.218633 cancer 0.578346 information 0.296506	CLICK HERE
1425	National Cancer Institute	Html	en	Ewing Sarcoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Ewing sarcoma.	ewing sarcoma 0.955451 Localized Ewing Sarcoma 0.516622 standard-risk Ewing sarcoma 0.50921 localized ewing tumors 0.458678 pelvic ewing sarcoma 0.53548 non-metastatic ewing 0.447666 Ewing family tumors 0.476484 Cooperative Ewing Sarcoma 0.57252 Primary Ewing tumor 0.442949 genetically confirmed Ewing 0.443739 recurrent Ewing sarcoma 0.50281 high-risk Ewing sarcoma 0.510965 soft tissue ewing 0.474262 Ewing sarcoma regimen 0.517079 Sarcoma Studies patients 0.436849 sarcoma treatment 0.437736 ewing sarcoma family 0.677203 Ewing sarcoma patients 0.582131 Ewing tumor patients 0.46609 Ewing Sarcoma Study 0.512708 radiation therapy 0.475396 Cutaneous Ewing sarcoma 0.543452 Ewing sarcoma trials 0.520061 extraosseous Ewing sarcoma. 0.438839 et al. 0.575718	extraskeletal Ewing sarcoma 0.55299 tissue Ewing sarcoma 0.517715 sarcoma family tumors 0.500986 Ewing sarcoma molecularly. 0.525686 nonmetastatic Ewing sarcoma 0.582468 secondary Ewing sarcoma 0.532715 PUBMED Abstract 0.436153 extraosseus Ewing tumors 0.450361 extraosseous ewing sarcoma 0.608612 Pediatr Blood Cancer 0.643087 prognosis Ewing family 0.435199 Intergroup Cooperative Ewing 0.452427 advanced Ewing tumors 0.44875 nonmetastatic extraosseous Ewing 0.439621 subcutaneous Ewing sarcoma 0.543232 Ewing sarcoma. 0.468942 primary Ewing sarcoma 0.527784 Abstract 0.588175 Clin Oncol 0.669349 multifocal Ewing sarcoma 0.559473 metastatic Ewing tumors 0.450872 Ewing tumor 0.52176 ewing tumors 0.573464 non metastatic Ewing 0.435213	CLICK HERE
1754	National Cancer Institute	Html	en	Breast Reconstruction After Mastectomy	A fact sheet that describes breast reconstruction after mastectomy, including surgical options, follow-up care, and breast cancer screening after reconstruction.	breast reduction surgery 0.28849 tissue breast reconstruction 0.452019 flap reconstruction 0.330223 immediate reconstruction 0.31662 tissue 0.60196 breast reconstruction surgery 0.457163 mastectomy 0.359177 implant 0.307847 implant reconstruction 0.254395 breast numbness 0.249047 donor tissue 0.258639 breast skin 0.288491 early-stage breast cancer 0.279638 natural breast shape 0.273514 pedicled flap reconstruction 0.298564 autologous tissue reconstruction 0.366797 breast cancer experience 0.279508 reconstructed breast 0.419512 autologous reconstruction 0.246473 tissue expander 0.25279 blood vessels 0.426971 chest wall tissue 0.239092 entire breast 0.302278 Delayed reconstruction 0.247408 breast cancer therapy 0.323533	radiation therapy 0.283075 breast reconstruction technique 0.360333 breast forms 0.256638 external breast prostheses 0.334034 women 0.280496 surgical nipple reconstruction 0.280177 breast reconstruction method 0.374498 breast reconstruction 0.909174 breast rebuilt 0.281588 free flap reconstruction 0.325097 breast cancer recurrence 0.30156 woman considering breast 0.279422 breast tissue 0.318522 flap 0.344123 sufficient breast volume 0.289888 autologous tissue 0.583784 Breast Implants page 0.303495 breast surgeons 0.246995 breast area 0.280597 breast cancer 0.510147 skin-sparing mastectomy 0.235094 Breast Disease 0.251106 inflammatory breast cancer 0.289892 chest tissue 0.237416	CLICK HERE
1868	National Cancer Institute	Html	es	Tratamiento del linfoma de Hodgkin infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del linfoma de Hodgkin infantil.	lymphocyte predominant hodgkin 0.379318 Cancer Statistics Review 0.310924 patients with hodgkin 0.340461 Epstein-Barr virus with 0.308343 lymphocyte predominance hodgkin 0.361894 Pediatric Lymphocyte-Predominant Hodgkin 0.335497 with nodular lymphocyte 0.31309 Epstein-Barr virus 0.324897 localized childhood hodgkin 0.334572 familial classical hodgkin 0.33579 células reed-sternberg 0.313182 Radiat Oncol Biol 0.310379 oncology group study 0.317944 adolescent hodgkin 0.33572 Children's Oncology Group 0.329911 Estados Unidos 0.310464 siguientes características 0.32336 Leuk Lymphoma 0.318529 hodgkin's lymphoma 0.723879 childhood hodgkin 0.361352 SEER Cancer Statistics 0.312001 classic hodgkin 0.335243 pediatric hodgkin 0.427701 IV Hodgkin 0.334995 adultos jóvenes 0.32544	estadio iv 0.319107 nodular lymphocyte-predominant hodgkin 0.387944 nodular sclerosing hodgkin 0.337374 high-risk hodgkin 0.334348 pediatric patients with 0.317448 with hodgkin 0.425646 linfadenopatía periférica 0.308361 non-Hodgkin's lymphoma 0.3114 advanced hodgkin 0.335086 National Cancer Institute 0.316464 report from 0.308961 with classical hodgkin 0.37144 Hodgkin's lymphoma after 0.346052 Epstein-Barr virus infection 0.309022 células reed-sternberg llamadas 0.308458 Pediatr Hematol Oncol 0.310971 Lymphoma project 0.310216 Clin Oncol 0.390721 Hodgkin Lymphoma Group 0.341816 Oncol Biol Phys 0.310469 hodgkin lymphoma 0.986519 lymphocyte-predominant hodgkin lymphoma 0.45063 Cancer Institute 0.316934 classical hodgkin lymphoma 0.529436	CLICK HERE
1998	National Cancer Institute	Html	es	Grados de comprobación científica de los estudios de cuidados médicos de apoyo (PDQ®)–Versión para profesionales de salud	Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos en los estudios de cuidados médicos de apoyo y cuidados paliativos.	Visuals Online 0.744337 siguientes aspectos 0.811238 conclusiones contradictorias 0.784508 Physician Data Query 0.788451 mejores datos 0.935432 siguientes parámetros 0.783558 siguientes fuentes 0.801613 quizás estén 0.788541	bibliografía biomédica 0.790209 siguientes datos 0.810319 National Cancer Institute 0.778122 numerosos sesgos 0.778964 siguientes riesgos 0.757344 determinado grupo 0.761778 siguientes temas 0.815552 Instituto Nacional 0.963601	CLICK HERE
2113	National Cancer Institute	Html	es	Exámenes de detección del cáncer de hígado (hepatocelular) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de hígado (hepatocelular).	chronic hepatitis b 0.350732 Cancer Res Clin 0.309514 cirrhotic patients monitored 0.308745 surgical treatment 0.304976 cases with 0.308289 Caucasian patients with 0.312453 CT-based tumor detection 0.30733 American Cancer Society 0.308532 infected with chronic 0.311933 clara preponderancia masculina 0.307413 patients with cirrhosis 0.329337 primary biliary cirrhosis 0.309915 to hepatocellular carcinoma 0.346439 Stroffolini T 0.311275 hepatocellular carcinoma 0.916421 Concurrent hepatitis 0.313581 Instituto Nacional 0.316611 risk factors 0.314635 PDQ Exámenes 0.318741 azar pacientes 0.307637 population-based study 0.305586 Baron RL 0.310966 Estados Unidos 0.349629 Serum tumor markers 0.306902 Cochrane Database Syst 0.306527	múltiples estudios 0.311385 patients with 0.460866 Fattovich G 0.312507 viral cirrhosis 0.306776 with chronic hepatitis 0.35842 screening technique 0.309776 identificó chc 0.327158 Prospective evaluation 0.305469 Sherman M 0.309865 Marsh JW Jr 0.306291 escasas ocasiones 0.326921 Expert Rev Anticancer 0.307784 National Cancer Institute 0.308331 serum alpha-fetoprotein levels 0.308165 Silent cirrhosis 0.306117 Aflatoxinas Asia 0.305041 De Maria N 0.306597 Physician Data Query 0.306315 etiología viral 0.305508 Horlander JC Sr 0.306639 alcoholic cirrhosis 0.306717 cáncer hepatocelular virus 0.320818 hepatitis aguda 0.31315 prospective study 0.328899	CLICK HERE
3423	National Cancer Institute	Html	es	Tintes para el cabello y el riesgo de cáncer	Hoja informativa que analiza las investigaciones sobre la posible conexión entre los tintes para el cabello de uso personal y el cáncer.	Garcia-Closas M 0.306371 Harling M 0.306346 La Vecchia C 0.308404 American Medical Association 0.308091 Personal permanent 0.308814 Costantini AS 0.305724 pequeño aumento 0.306764 lymphoid neoplasms 0.305705 case-control study 0.330749 sustancias químicas llamadas 0.319289 linfoma no-Hodgkin 0.315605 IARC Monographs 0.307567 New England bladder 0.317677 dye products 0.311357 Benvenuti A 0.306313 Occupational Health 0.305772 Sanjose S 0.317218 Estados Unidos 0.315003 resultados contradictorios 0.358008 hematolymphopoietic malignancies 0.305757 PubMed Abstract 0.927635 on carcinogenicity 0.306299 International Agency 0.31736 International Journal 0.345823 análisis conjunto 0.313039	Nieters A 0.306464 Bolt HM 0.305479 Critical Reviews 0.305548 Nienhaus A 0.305624 leucemia aguda 0.319649 non-Hodgkin lymphoma 0.305903 is not 0.31478 Carcinogenic Risks 0.30569 aminas aromáticas 0.321464 Dulon M 0.30623 Epidemiology Biomarkers 0.309054 Thun MJ 0.305441 Etminan M 0.306466 Hamann CR 0.305758 determinados tipos 0.306529 Kogevinas M 0.306372 Aben KK 0.305435 Gago-Dominguez M 0.314868 Sandler DP 0.305457 case-control study from 0.31306 Some Aromatic Amines 0.30908 Schablon A 0.305625 Montes-Martinez A 0.305837 Decarli A 0.305736	CLICK HERE
15650	National Cancer Institute	Html	en	Step 2: Application Receipt & Assignment	Information on the assignment numbers the Center for Scientific Review (CSR) creates once an application is submitted and other submission policies.	Application Type 0.237536 100,228th application 0.228911 program director 0.554123 peer review process 0.902016 initial peer review 0.326681 Scientific Review 0.216004 new application 0.239088 specific application 0.226573 Resubmission Applications 0.206964 research grant applications 0.359218 his/her assigned application 0.489157 specific budgetary limits 0.31822 Program Announcements 0.201839	pre-announced Request 0.201939 appropriate application form 0.353459 new grant 0.218872 NIH peer review 0.369648 Incomplete applications 0.208003 NCI program director 0.428336 suffix code 0.378185 grant numbers 0.228139 application 0.702093 NIH Policy 0.353037 traditional research project 0.330544 central receipt point 0.406816	CLICK HERE
16830	National Cancer Institute	Html	en	Clinical Trial Sequencing Project	null	gene expression test 0.968523 vital genomic information 0.445867 non-metastatic RCC 0.377128 breast cancer response 0.478667 Large B Cell 0.384272 NCTN clinical trials 0.448807 ECOG-ACRIN E2805 trial 0.421922 DLBCL patients 0.352651 National Clinical Trials 0.46574 molecular basis 0.431838 advanced RCC 0.374566 clinical trials 0.533121 VEGF inhibitors 0.375945 clinical trial 0.642586 RCC development 0.370697 breast cancer patients 0.519364 comprehensive molecular analysis 0.404401 Genomic Data Commons 0.460933 Trial Assigning Individualized 0.463121 cancer types 0.360865 surgical removal 0.412464 chemotherapy best complements 0.471441 large B-cell lymphoma 0.45172 cancer recurrence 0.405985 low-risk patients 0.363667	clinically helpful tool 0.4004 rich molecular data 0.400698 Combination Chemotherapy 0.375651 cancer research community 0.644574 adult non-Hodgkin lymphoma 0.414301 Her2-negative breast cancer 0.645596 NCI-sponsored clinical trial 0.620071 common kidney cancer 0.437411 endothelial growth factor 0.403689 different chemotherapy regimens 0.474741 human epidermal growth 0.418539 anonymized clinical data 0.446701 genomic alterations 0.360205 CCG 0.375478 NCI-sponsored clinical trials 0.472546 pathway drives RCC 0.461359 breast cancer 0.780189 best individualized treatment 0.43596 Clinical Trial Sequencing 0.508554 tissue samples 0.518757 breast cancer treatments 0.478341 renal cell carcinoma 0.625007 New England Journal 0.405702 Diffuse Large 0.405055	CLICK HERE
17243	National Cancer Institute	Html	es	Conversación sobre el cáncer avanzado	Aprenda formas de comunicarse con su médico y con sus seres queridos, y cómo recibir apoyo si tiene cáncer avanzado.	cuánto tiempo 0.910821 Dígales cuáles 0.675552 Is Being Treated 0.579455 Someone You Love 0.717833	inglés when someone 0.582776 Mucha gente 0.551036 When Someone You 0.727905 Deles tiempo 0.577854	CLICK HERE